{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=36", "query": { "intervention": "Formulation #2", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1745, "total_pages": 175, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T00:09:01.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00988624", "title": "A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease", "Huntington Disease" ], "interventions": [ { "name": "Dimebon IR Tablet", "type": "DRUG" }, { "name": "Dimebon MR1", "type": "DRUG" }, { "name": "Dimebon MR2", "type": "DRUG" }, { "name": "Dimebon MR3", "type": "DRUG" }, { "name": "Dimebon MR4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2009-10", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-01-12", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00988624" }, { "nct_id": "NCT04583618", "title": "Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Immunization" ], "interventions": [ { "name": "Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13 - valent conjugate vaccine-Prevnar 13", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Vaccine Polyvalent-Pneumovax 23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "50 Years to 84 Years" }, "enrollment_count": 750, "start_date": "2020-10-08", "completion_date": "2022-01-20", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 17, "location_summary": "Anaheim, California • Rolling Hills Estates, California • Wheat Ridge, Colorado + 14 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583618" }, { "nct_id": "NCT07455825", "title": "A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 65, "start_date": "2026-03-05", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07455825" }, { "nct_id": "NCT02227940", "title": "Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "ALK Positive", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-01-08", "completion_date": "2019-02-12", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227940" }, { "nct_id": "NCT04580797", "title": "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "PF-06700841 IR", "type": "DRUG" }, { "name": "PF-06700841 MR1", "type": "DRUG" }, { "name": "PF-06700841 MR2", "type": "DRUG" }, { "name": "PF-06700841 MR3", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2020-10-02", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2021-03-08", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 2, "location_summary": "Coral Gables, Florida • Miami, Florida", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580797" }, { "nct_id": "NCT01676220", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" }, { "name": "Lantus (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 117, "location_summary": "Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676220" }, { "nct_id": "NCT01427582", "title": "YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-09-01", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427582" }, { "nct_id": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Pleural Disease", "Mesothelioma", "Metastases", "Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "iCasp9M28z T cell infusions", "type": "GENETIC" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2015-05", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414269" }, { "nct_id": "NCT06674941", "title": "A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Teprotumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2023-03-24", "completion_date": "2023-11-14", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06674941" }, { "nct_id": "NCT02370680", "title": "Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Aspirin", "type": "DRUG" }, { "name": "Durlaza™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Haven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-02", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-08-06", "last_synced_at": "2026-11-06T00:09:01.504Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370680" } ] }